| http://www.w3.org/ns/prov#value | - issued by the US Food and Drug Administration after it detected quality problems across the Indian drugmaker???s network.Sarbjit Kour Nanga, an analyst from Angel Broking, told in-Pharmatechnologist.com Ranbaxy???s latest production halt was a direct response and designed to give the firm time to rectify problems at both the Tonsa site and the Dewas facility, which was also included in the consent
|
